Hector Nazario, MD
Transplant Hepatology · Dallas, TXNPI 1437160827
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $129,265 of the $160,882 with a category attached, or 80.3%. 25 manufacturers reported payments, led by Gilead at 51.3% of the total. Reporting peaked in 2019 at $54,737 and has fallen 69.5% since, to $16,695 in 2025.
Across 542 payments — averaging $296.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$83K
- AbbVie$75K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Intercept Pharmaceuticals, Inc.$374
- Madrigal Pharmaceuticals$354
- Ipsen Biopharmaceuticals, Inc$177
- plus $659 from 19 others
Across 6 payments — averaging $11,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$64K
- Gilead$2K
What the payments were for
- Consulting fees$6,9904%
- Speaking & faculty fees$129,26580%
- Travel & lodging$12,5488%
- Food & beverage$12,0798%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 203 | $82,552 |
| AbbVie | 205 | $75,042 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 65 | $1,724 |
| Intercept Pharmaceuticals, Inc. | 19 | $374 |
| Madrigal Pharmaceuticals | 12 | $354 |
| Ipsen Biopharmaceuticals, Inc | 9 | $177 |
| Novo Nordisk | 2 | $101 |
| Siemens Medical Solutions USA, Inc. | 5 | $73 |
| Eisai Inc. | 3 | $60 |
| Mallinckrodt Hospital Products Inc. | 1 | $50 |
| Intra-sana Laboratories | 2 | $39 |
| Laborie Medical Technologies Corp. | 1 | $38 |
| Merck | 2 | $33 |
| AstraZeneca | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Fujifilm Healthcare Americas Corporation | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| VBI Vaccine (delaware) Inc. | 1 | $27 |
| Shionogi Inc | 1 | $26 |
| Amgen | 1 | $20 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Eton Pharmaceuticals, Inc. | 1 | $17 |
| Mirum Pharmaceuticals, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$160,882 in reported general payments places this provider in the 75th percentile of 28 transplant hepatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 29 | $693,584 |
| XifaxanRifaximin | 128 | $405,450 |
| VemlidyTenofovir Alafenamide | 98 | $166,276 |
| OcalivaObeticholic Acid | 16 | $154,177 |
| Ursodiol | 453 | $62,983 |
| Tacrolimus | 160 | $15,111 |
| Mycophenolate Mofetil | 126 | $7,300 |
| Lactulose | 89 | $3,613 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 22 | $3,177 |
| Tenofovir Disoproxil Fumarate | 23 | $1,547 |
| Nadolol | 37 | $1,270 |
| Spironolactone | 108 | $1,267 |
| Azathioprine | 41 | $1,019 |
| ConstuloseLactulose | 33 | $812 |
| Pantoprazole Sodium | 153 | $743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $82,552 | $859,860127 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $1,724 | $408,627150 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $374 | $154,17716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 28 transplant hepatology providers in Texas.
Other transplant hepatology in Dallas
- Ashwini MehtaDallas$100K
- Mangesh PagadalaDallas$84K
- Maisha BarnesDallas$12K
- Adil HabibDallas$5K
- Amar MahgoubDallas$982
- Sumeet AsraniDallas$878
- Abdullah MubarakTyler$362K
- Stevan GonzalezFort Worth$282K
- Fernando MembrenoMcAllen$258K
- David VictorHouston$249K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.